Marco is a trader of stocks, options, currencies, and futures. He has been fascinated with the financial markets ever since he bought his first stock at 11 years old. Marco entered the business world at the age of 13, with the creation of an extremely successful retail website, that of which he... More
As stated on April 27 of this year in my blog post U.S. Futures Looking Dismal but Possible Swine Flu Profit Play, I gave you a look at how the media plays a role in helping stocks performance over a period of time. Since then the H1N1 Flu (Swine Flu) has been declared a pandemic. Although I don't expect the media to be reporting about the Swine Flu too much over the next week or two, unless something drastic happens (due to other stories that have crept up recently), this is still an issue we have to deal with, and don't think drug companies have stopped the R&D process on finding another pill.
I was doing my nightly research and I noticed an unbelievable amount of stocks from the healthcare sector (Biotech and Drugs) which have been strong the last 30 days (Swine Flu has been a popular topic in the media over the past 30 days, but note that all of the companies in this article are not trying to develop a vaccine for the Swine Flu, but are in the healthcare sector), and are still demonstrating strength on the technical level. The ratio used in evaluating these stocks is called the Bull:Bear ratio, which is defined on my blog post Bull Bear Ratio Defined. I don't like using just one piece of software so I go to another source which is Investor's Business Daily (IBD) as they give a very nice composite rating for these stocks. For details on how IBD ranks these stocks check out my blog post One of My Methods to Finding Bullish Stocks.
So on with the list of stocks. I have put together a list of stocks below with both the Bull to Bear ratio as well as the IBD composite rating. All stocks were evaluated as of pre-market June 26, 2009 and are ranked alphabetically in the table below. I will let you know the stocks I am most interested in and the strategy I intend to use when purchasing them.
Company
Ticker
IBD Rating
Bull: Bear Ratio
Abaxis Inc
ABAX
83
11:1
Acorda Therapeutics Inc
ACOR
49
12:0
Alexion Pharmaceuticals Inc
ALXN
98
10:2
Alexza Pharmaceuticals Inc
ALXA
28
10:1
Alkermes Inc
ALKS
38
10:2
Auxilium Pharmaceuticals Inc
AUXL
31
11:1
Avanir Pharmaceuticals Inc
AVNR
92
13:0
Biovail Corp
BVF
87
13:0
Celgene Corp
CELG
91
11:1
Charles River Laboratories International Inc
CRL
53
8:4
Chattem Inc
CHTT
78
7:4
Dr Reddy Labs Depository Receipt
RDY
95
13:2
Endo Pharmaceuticals Holdings Inc
ENDP
78
10:1
Forest Laboratories Inc
FRX
51
11:2
Gilead Sciences Inc
GILD
98
9:2
Hospira Inc
HSP
95
11:0
InterMune Inc
ITMN
22
12:1
Ista Pharmaceuticals Inc
ISTA
95
13:0
Jazz Pharmaceuticals Inc
JAZZ
74
10:1
Meridian Bioscience Inc
VIVO
84
10:2
Metabolix Inc
MBLX
23
11:1
Momenta Pharmaceuticals Inc
MNTA
19
14:1
Myriad Genetics Inc
MYGN
93
10:3
Noven Pharmaceuticals Inc
NOVN
98
14:0
Orexigen Therapeutics Inc
OREX
58
12:1
Savient Pharmaceuticals Inc
SVNT
51
12:1
United Therapeutics Corp
UTHR
98
10:1
Valeant Pharmaceuticals International
VRX
99
13:1
Vertex Pharmaceuticals Inc
VRTX
55
13:0
Watson Pharmaceuticals Inc
WPI
91
12:1
From the list above the stocks I like the most and believe have a good chance of being winners in the near future are Valeant (VRX), Noven Pharamaceuticals (NOVN), and Ista Pharmaceuticals (ISTA).
Strategies I'll be using
Strategy #1: Valeant showed up in this list and was a stock I've been bullish on since April 27 as you can see from my blog post linked to in the first paragraph. I think this stock has some upside left and I am going to be more aggressive and speculate by being the buyer of call options on this stock. I am currently looking at the September 25 Calls which can be purchased for less than 10% the cost of the stock price at close, therefore a 10% move up in the stock will give me my money back and a return. Not to mention this stock is trading above 26 which puts this call option already in the money by $1.18 a share. This stock has nearly doubled since I first blogged about it, and it could go down just as fast. This is the reason I may be purchasing calls in the money versus the common shares of this stock. To learn more about trading options click here.
Strategy #2: I was thinking of using the buy/write option strategy for this stock, however If I purchased the stock I am afraid I would not be able to write out any options on it, as the options on this stock are almost illiquid. For this I would use the simplest strategy of all, and buy common shares. I would look to get in on weakness though, such as a 7%-10% pull back. Once I hold the stock I will monitor the options market to see if a decent premium can be made on heavier (more liquid) options volume.
Strategy #3: ISTA more than doubled since my blog post on April 27, but is still strong in both of my ratings obtained. The stock made a new 52 week high June 25, 2009 at 4.40 before closing at $4.19 a share. This stock looks like it wants to continue the breakout, and could very well do so. I am looking to accumulate common shares of this stock, as options are not issued on this stock. Again I will look to purchase shares on weakness, such as a 7%-10%.
To get a printable list of the 30 stocks in the table ranked by Bull: Bear Ratio as well as by IBD score click here.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha
community. Instablog posts are not selected, edited or screened by Seeking Alpha editors,
in contrast to contributors' articles.
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
Profit from a Pandemic: 30 Bullish Biotech & Drug Stocks to Watch 0 comments
As stated on April 27 of this year in my blog post U.S. Futures Looking Dismal but Possible Swine Flu Profit Play, I gave you a look at how the media plays a role in helping stocks performance over a period of time. Since then the H1N1 Flu (Swine Flu) has been declared a pandemic. Although I don't expect the media to be reporting about the Swine Flu too much over the next week or two, unless something drastic happens (due to other stories that have crept up recently), this is still an issue we have to deal with, and don't think drug companies have stopped the R&D process on finding another pill.
I was doing my nightly research and I noticed an unbelievable amount of stocks from the healthcare sector (Biotech and Drugs) which have been strong the last 30 days (Swine Flu has been a popular topic in the media over the past 30 days, but note that all of the companies in this article are not trying to develop a vaccine for the Swine Flu, but are in the healthcare sector), and are still demonstrating strength on the technical level. The ratio used in evaluating these stocks is called the Bull:Bear ratio, which is defined on my blog post Bull Bear Ratio Defined. I don't like using just one piece of software so I go to another source which is Investor's Business Daily (IBD) as they give a very nice composite rating for these stocks. For details on how IBD ranks these stocks check out my blog post One of My Methods to Finding Bullish Stocks.
So on with the list of stocks. I have put together a list of stocks below with both the Bull to Bear ratio as well as the IBD composite rating. All stocks were evaluated as of pre-market June 26, 2009 and are ranked alphabetically in the table below. I will let you know the stocks I am most interested in and the strategy I intend to use when purchasing them.
From the list above the stocks I like the most and believe have a good chance of being winners in the near future are Valeant (VRX), Noven Pharamaceuticals (NOVN), and Ista Pharmaceuticals (ISTA).
Strategies I'll be using
Strategy #1: Valeant showed up in this list and was a stock I've been bullish on since April 27 as you can see from my blog post linked to in the first paragraph. I think this stock has some upside left and I am going to be more aggressive and speculate by being the buyer of call options on this stock. I am currently looking at the September 25 Calls which can be purchased for less than 10% the cost of the stock price at close, therefore a 10% move up in the stock will give me my money back and a return. Not to mention this stock is trading above 26 which puts this call option already in the money by $1.18 a share. This stock has nearly doubled since I first blogged about it, and it could go down just as fast. This is the reason I may be purchasing calls in the money versus the common shares of this stock. To learn more about trading options click here.
Strategy #2: I was thinking of using the buy/write option strategy for this stock, however If I purchased the stock I am afraid I would not be able to write out any options on it, as the options on this stock are almost illiquid. For this I would use the simplest strategy of all, and buy common shares. I would look to get in on weakness though, such as a 7%-10% pull back. Once I hold the stock I will monitor the options market to see if a decent premium can be made on heavier (more liquid) options volume.
Strategy #3: ISTA more than doubled since my blog post on April 27, but is still strong in both of my ratings obtained. The stock made a new 52 week high June 25, 2009 at 4.40 before closing at $4.19 a share. This stock looks like it wants to continue the breakout, and could very well do so. I am looking to accumulate common shares of this stock, as options are not issued on this stock. Again I will look to purchase shares on weakness, such as a 7%-10%.
To get a printable list of the 30 stocks in the table ranked by Bull: Bear Ratio as well as by IBD score click here.
Disclosure: No Positions
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Latest Followers
StockTalks
-
Sep 09, 2009
-
Aug 10, 2009
-
Jul 16, 2009
More »Posts by Ticker
Latest Comments
Most Commented
Posts by Themes